Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 2 · 28.6%High 3 · 42.9%

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Progression‐free survival · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.89 [0.81, 0.98]
4 studies · 3699 participants
Moderate

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Overall survival (OS) · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in overall survival (OS) compared with tri‐weekly paclitaxel plus carboplatin (high certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.92 [0.79, 1.06]
4 studies · 3699 participants
High

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.11 [0.86, 1.43]
4 studies · 3639 participants
Moderate

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Grade 3 and 4 hematological adverse events (AE) ‐ anemia · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin leads to higher haematological adverse event: Grade 3/4 anaemia compared with tri‐weekly paclitaxel plus carboplatin (high certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.57 [1.12, 2.2]
4 studies · 3639 participants
High

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in neurological adverse event: Grade 3/4 neuropathy, not otherwise… compared with tri‐weekly paclitaxel plus carboplatin (low certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.12 [0.64, 1.94]
4 studies · 3639 participants
Low

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Overall Survivalclinical observation · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel showed no clear difference in overall Survivalclinical observation compared with carboplatin+Paclitaxel (high certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.02 [0.97, 1.06]
2 studies · 1998 participants
High

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Progression‐free survival · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel may leads to higher progress free survival compared with carboplatin+Paclitaxel (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.03 [1.03, 1.03]
2 studies · 1998 participants
Low